Gastritis classification: Difference between revisions
No edit summary |
m (Bot: Removing from Primary care) |
||
(6 intermediate revisions by 2 users not shown) | |||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. In clinical practice, | The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. In clinical practice, gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting [[gastric]] histology. Gastritis staging combines the [[atrophy]] score which is determined by biopsy and the [[atrophy]] topography which is determined by directed [[biopsy]] mapping. | ||
==Classification== | ==Classification== | ||
*The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. <ref name="pmid8827022">{{cite journal| author=Dixon MF, Genta RM, Yardley JH, Correa P| title=Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. | journal=Am J Surg Pathol | year= 1996 | volume= 20 | issue= 10 | pages= 1161-81 | pmid=8827022 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8827022 }} </ref> | *The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. <ref name="pmid8827022">{{cite journal| author=Dixon MF, Genta RM, Yardley JH, Correa P| title=Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. | journal=Am J Surg Pathol | year= 1996 | volume= 20 | issue= 10 | pages= 1161-81 | pmid=8827022 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8827022 }} </ref><br /> | ||
<br /> | |||
{| | {| | ||
! colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Classification and grading of Gastritis: Updated Sydney System''' | ! colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''Classification and grading of Gastritis: Updated Sydney System''' | ||
Line 16: | Line 15: | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Gastritis synonyms | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Gastritis synonyms | ||
|- | |- | ||
| colspan="2" style="background:#DCDCDC;" align="center" + | Non-atrophic | | colspan="2" style="background:#DCDCDC;" align="center" + | '''Non-atrophic''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Helicobacter pylori | *''[[Helicobacter pylori]]'' | ||
*Other factors | *Other factors | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
Line 28: | Line 27: | ||
*Type B* | *Type B* | ||
|- | |- | ||
| rowspan="4" style="background:#DCDCDC;" align="center" + |Atrophic | | rowspan="4" style="background:#DCDCDC;" align="center" + |'''Atrophic''' | ||
| style="background:#DCDCDC;" align="center" + |Autoimmune | | style="background:#DCDCDC;" align="center" + |'''Autoimmune''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Autoimmunity | *[[Autoimmunity]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Type A* | *Type A* | ||
*Diffuse corporal | *Diffuse corporal | ||
*Pernicious anemia-associated | *[[Pernicious anemia]]-associated | ||
|- | |- | ||
| rowspan="3" style="background:#DCDCDC;" align="center" + |Multifocal atrophic | | rowspan="3" style="background:#DCDCDC;" align="center" + |'''Multifocal atrophic''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Helicobacter pylori | *''[[Helicobacter pylori]]'' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Type B*, type AB* | *Type B*, type AB* | ||
Line 53: | Line 52: | ||
*Metaplastic | *Metaplastic | ||
|- | |- | ||
| rowspan="21" style="background:#DCDCDC;" align="center" + | Special forms | | rowspan="21" style="background:#DCDCDC;" align="center" + | '''Special forms''' | ||
| rowspan="4" style="background:#DCDCDC;" align="center" + | Chemical | | rowspan="4" style="background:#DCDCDC;" align="center" + | '''Chemical''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Chemical irritation | *Chemical irritation | ||
Line 61: | Line 60: | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Bile | *[[Bile]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Reflux | *Reflux | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*NSAIDs | *[[NSAIDs]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*NSAID | *[[NSAID]] | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
Line 75: | Line 74: | ||
*Type C | *Type C | ||
|- | |- | ||
| style="background:#DCDCDC;" align="center" + |Radiation | | style="background:#DCDCDC;" align="center" + |'''Radiation''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Radiation injury | *[[Radiation injury]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| rowspan="4" style="background:#DCDCDC;" align="center" + |Lymphocytic | | rowspan="4" style="background:#DCDCDC;" align="center" + |'''Lymphocytic''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Idiopathic? Immune mechanisms | *Idiopathic? [[Immune]] mechanisms | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Varioliform (endoscopic) | *Varioliform ([[endoscopic]]) | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Gluten | *[[Gluten]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Celiac disease-associated | *[[Celiac disease]]-associated | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Drug (ticlopidine) | *Drug ([[ticlopidine]]) | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
* | *''[[Helicobacter pylori]]'' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| rowspan="5" style="background:#DCDCDC;" align="center" + |Noninfectious granulomatous | | rowspan="5" style="background:#DCDCDC;" align="center" + |'''Noninfectious granulomatous''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Crohn's disease | *[[Crohn's disease]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Sarcoidosis | *[[Sarcoidosis]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Granulomatosis with polyangiitis and other vasculitides | *[[Granulomatosis with polyangiitis]] and other [[vasculitides]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
Line 119: | Line 118: | ||
*Idiopathic | *Idiopathic | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Isolated granulomatous | *Isolated [[granulomatous]] | ||
|- | |- | ||
| rowspan="2" style="background:#DCDCDC;" align="center" + |Eosinophilic | | rowspan="2" style="background:#DCDCDC;" align="center" + |'''Eosinophilic''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Food sensitivity | *[[Food allergy|Food sensitivity]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Allergic | *[[Allergic]] | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Other allergies | *Other [[allergies]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|- | |- | ||
| rowspan="2" style="background:#DCDCDC;" align="center" + |Other infectious gastritides | | rowspan="2" style="background:#DCDCDC;" align="center" + |'''Other infectious gastritides''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Bacteria (other than | *[[Bacteria]] (other than ''[[Helicobacter pylori]]'') | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Phlegmonous | *Phlegmonous | ||
|- | |- | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Viruses | *[[Viruses]] | ||
*Fungi | *[[Fungi]] | ||
*Parasites | *[[Parasites]] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
|} | |} | ||
<br /> | <br /> | ||
<br /> | <br /> | ||
*In clinical practice, | *In clinical practice, gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the atrophy score which is determined by biopsy and the atrophy topography which is determined by directed biopsy mapping. <ref name="pmid17142647">{{cite journal| author=Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G et al.| title=Gastritis staging in clinical practice: the OLGA staging system. | journal=Gut | year= 2007 | volume= 56 | issue= 5 | pages= 631-6 | pmid=17142647 | doi=10.1136/gut.2006.106666 | pmc=1942143 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17142647 }} </ref> <ref name="pmid18424244">{{cite journal| author=Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K et al.| title=OLGA staging for gastritis: a tutorial. | journal=Dig Liver Dis | year= 2008 | volume= 40 | issue= 8 | pages= 650-8 | pmid=18424244 | doi=10.1016/j.dld.2008.02.030 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18424244 }} </ref> | ||
<br /> | <br /> | ||
{| | {| | ||
Line 153: | Line 152: | ||
! colspan="4" style="background:#4479BA; color: #FFFFFF;" + | '''Corpus''' | ! colspan="4" style="background:#4479BA; color: #FFFFFF;" + | '''Corpus''' | ||
|- | |- | ||
! style="background:#DCDCDC; + | ! style="background:#DCDCDC;" align="center" + | No Atrophy (Score: 0) | ||
! style="background:#DCDCDC; + | ! style="background:#DCDCDC;" align="center" + | Mild Atrophy (Score: 1) | ||
! style="background:#DCDCDC; + | ! style="background:#DCDCDC;" align="center" + | Moderate Atrophy (Score: 2) | ||
! style="background:#DCDCDC; + | ! style="background:#DCDCDC;" align="center" + | Severe Atrophy (Score: 3) | ||
|- | |- | ||
! rowspan="4" style="background:#7d7d7d; color: #FFFFFF;" + | | ! rowspan="4" style="background:#7d7d7d; color: #FFFFFF;" align="center" + | | ||
A | A | ||
Line 171: | Line 170: | ||
M | M | ||
! style="background:#DCDCDC; + | ! style="background:#DCDCDC;" align="center" + | No Atrophy (Score: 0) (''including incisura angularis'') | ||
| STAGE 0 | | style="background:#F5F5F5;" align="center" + | STAGE 0 | ||
| STAGE I | | style="background:#F5F5F5;" align="center" + | STAGE I | ||
| STAGE II | | style="background:#F5F5F5;" align="center" + | STAGE II | ||
| STAGE II | | style="background:#F5F5F5;" align="center" + | STAGE II | ||
|- | |- | ||
! style="background:#DCDCDC; + | ! style="background:#DCDCDC;" align="center" + | Mild Atrophy (Score: 1) (''including incisura angularis'') | ||
| style="background:#F5F5F5;" align="center" + | STAGE I | |||
| STAGE I | | style="background:#F5F5F5;" align="center" + | STAGE I | ||
| STAGE I | | style="background:#F5F5F5;" align="center" + | STAGE II | ||
| STAGE II | | style="background:#F5F5F5;" align="center" + | STAGE III | ||
| STAGE III | |||
|- | |- | ||
! style="background:#DCDCDC; + | ! style="background:#DCDCDC;" align="center" + | Moderate Atrophy (Score: 2) (''including incisura angularis'') | ||
| style="background:#F5F5F5;" align="center" + | STAGE II | |||
| STAGE II | | style="background:#F5F5F5;" align="center" + | STAGE II | ||
| STAGE II | | style="background:#F5F5F5;" align="center" + | STAGE III | ||
| STAGE III | | style="background:#F5F5F5;" align="center" + | STAGE IV | ||
| STAGE IV | |||
|- | |- | ||
! style="background:#DCDCDC; + | ! style="background:#DCDCDC;" align="center" + | Severe Atrophy (Score: 3) (''including incisura angularis'') | ||
| style="background:#F5F5F5;" align="center" + | STAGE III | |||
| STAGE III | | style="background:#F5F5F5;" align="center" + | STAGE III | ||
| STAGE III | | style="background:#F5F5F5;" align="center" + | STAGE IV | ||
| STAGE IV | | style="background:#F5F5F5;" align="center" + | STAGE IV | ||
| STAGE IV | |||
|} | |} | ||
Line 208: | Line 204: | ||
! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" + | Grading guidelines | ! colspan="1" rowspan="1" style="background:#4479BA; color: #FFFFFF;" + | Grading guidelines | ||
|- | |- | ||
| style="background:#DCDCDC; + " | Chronic inflammation | | style="background:#DCDCDC; + " | '''Chronic inflammation''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Increased [[lymphocytes]] and [[plasma cells]] in [[lamina propria]] | *Increased [[lymphocytes]] and [[plasma cells]] in [[lamina propria]] | ||
Line 214: | Line 210: | ||
* Mild, moderate or severe increase in density | * Mild, moderate or severe increase in density | ||
|- | |- | ||
| style="background:#DCDCDC; + " | Activity | | style="background:#DCDCDC; + " | '''Activity''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*[[Neutrophil|Neutrophilic]] infiltrates of the [[lamina propria]], pits or surface [[epithelium]] | *[[Neutrophil|Neutrophilic]] infiltrates of the [[lamina propria]], pits or surface [[epithelium]] | ||
Line 222: | Line 218: | ||
* Severe: more than two-thirds | * Severe: more than two-thirds | ||
|- | |- | ||
| style="background:#DCDCDC; + " | [[Atrophy]] | | style="background:#DCDCDC; + " | [[Atrophy|'''Atrophy''']] | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Loss of specialized glands from either antrum or corpus | *Loss of specialized glands from either [[antrum]] or corpus | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
* Mild, moderate, or severe loss | * Mild, moderate, or severe loss | ||
|- | |- | ||
| style="background:#DCDCDC; + " | ''[[Helicobacter pylori]]'' | | style="background:#DCDCDC; + " | ''[[Helicobacter pylori|'''Helicobacter pylori''']]'' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*''[[H. pylori]]'' density | *''[[H. pylori]]'' density | ||
Line 236: | Line 232: | ||
* Severe colonization: large clusters or a continuous layer over two-thirds of surface | * Severe colonization: large clusters or a continuous layer over two-thirds of surface | ||
|- | |- | ||
| style="background:#DCDCDC; + " | Intestinal [[Metaplasia]] | | style="background:#DCDCDC; + " | '''Intestinal [[Metaplasia]]''' | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
*Intestinal [[metaplasia]] of the epithelium | *[[Intestinal]] [[metaplasia]] of the epithelium | ||
| style="background:#F5F5F5; + " | | | style="background:#F5F5F5; + " | | ||
* Mild: less than one-third of mucosa involved | * Mild: less than one-third of mucosa involved | ||
Line 248: | Line 244: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
| |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Up-To-Date]] |
Latest revision as of 21:49, 29 July 2020
Gastritis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Gastritis classification On the Web |
American Roentgen Ray Society Images of Gastritis classification |
Risk calculators and risk factors for Gastritis classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]}}
Overview
The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. In clinical practice, gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the atrophy score which is determined by biopsy and the atrophy topography which is determined by directed biopsy mapping.
Classification
- The Updated Sydney System establishes the classification and grading of gastritis which underlines the significance of combining topographical, morphological, and etiological information to help arrive at clinical diagnosis. [1]
Classification and grading of Gastritis: Updated Sydney System | |||
---|---|---|---|
Type of Gastritis | Etiology | Gastritis synonyms | |
Non-atrophic |
|
| |
Atrophic | Autoimmune |
| |
Multifocal atrophic |
| ||
|
| ||
|
| ||
Special forms | Chemical |
|
|
| |||
|
| ||
Radiation | |||
Lymphocytic |
|
| |
| |||
|
|||
Noninfectious granulomatous | |||
|
|||
|
|||
|
| ||
Eosinophilic | |||
|
|||
Other infectious gastritides |
|
| |
- In clinical practice, gastritis staging is done using the OLGA (Operative Link on Gastritis Assessment) staging system for reporting gastric histology. Gastritis staging combines the atrophy score which is determined by biopsy and the atrophy topography which is determined by directed biopsy mapping. [2] [3]
Gastritis staging in clinical practice: The OLGA staging system | |||||
---|---|---|---|---|---|
Atrophy Score | Corpus | ||||
No Atrophy (Score: 0) | Mild Atrophy (Score: 1) | Moderate Atrophy (Score: 2) | Severe Atrophy (Score: 3) | ||
A N T R U M |
No Atrophy (Score: 0) (including incisura angularis) | STAGE 0 | STAGE I | STAGE II | STAGE II |
Mild Atrophy (Score: 1) (including incisura angularis) | STAGE I | STAGE I | STAGE II | STAGE III | |
Moderate Atrophy (Score: 2) (including incisura angularis) | STAGE II | STAGE II | STAGE III | STAGE IV | |
Severe Atrophy (Score: 3) (including incisura angularis) | STAGE III | STAGE III | STAGE IV | STAGE IV |
Sydney system for grading of chronic gastritis[1]
Sydney system for grading of Chronic Gastritis | ||
---|---|---|
Feature | Definition | Grading guidelines |
Chronic inflammation |
|
|
Activity |
|
|
Atrophy |
|
|
Helicobacter pylori |
|
|
Intestinal Metaplasia |
|
|
References
- ↑ 1.0 1.1 Dixon MF, Genta RM, Yardley JH, Correa P (1996). "Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994". Am J Surg Pathol. 20 (10): 1161–81. PMID 8827022.
- ↑ Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G; et al. (2007). "Gastritis staging in clinical practice: the OLGA staging system". Gut. 56 (5): 631–6. doi:10.1136/gut.2006.106666. PMC 1942143. PMID 17142647.
- ↑ Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K; et al. (2008). "OLGA staging for gastritis: a tutorial". Dig Liver Dis. 40 (8): 650–8. doi:10.1016/j.dld.2008.02.030. PMID 18424244.